Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
9.25
-2.25 (-19.57%)
Mar 31, 2025, 2:33 PM EDT - Market open
Capricor Therapeutics Employees
Capricor Therapeutics had 160 employees as of December 31, 2024. The number of employees increased by 58 or 56.86% compared to the previous year.
Employees
160
Change (1Y)
58
Growth (1Y)
56.86%
Revenue / Employee
$139,190
Profits / Employee
-$252,920
Market Cap
422.50M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CAPR News
- 11 days ago - Capricor Therapeutics, Inc. (CAPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - GlobeNewsWire
- 21 days ago - FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment - PRNewsWire
- 24 days ago - Capricor Therapeutics to Present at Leerink's Global Healthcare Conference 2025 - GlobeNewsWire
- 26 days ago - Capricor: Further Value Unlocked With Priority Review Of Deramiocel - Seeking Alpha
- 27 days ago - Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - Benzinga
- 5 weeks ago - Capricor Therapeutics: Heavily Derisked After BLA Submission And OLE Data - Seeking Alpha